Aegis Oral Drug-Delivery Technology Used in Antisense Primate Study
Drug delivery firm Aegis Therapeutics said this week that an undisclosed partner has successfully used the company’s Intravail transmucosal absorption enhancement technology to orally delivery a preclinical antisense drug to six primates.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
